There Are Currently over 190 Apoptopic Drugs in Active Development for the Treatment of More Than 40 Different Cancer Indications.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48447) has announced the addition of the new Bioseeker report "Competitive Outlook on Apoptosis in Oncology" to their offering. Cancer cells frequently and possibly invariably in·var·i·a·ble adj. Not changing or subject to change; constant. in·var  i·a·bil possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells. Scope of this report * In-depth competitive landscape assessment of the apoptopic market in oncology * Thorough review of utilized targets in apoptopic drug development * Thorough review of approved drugs * Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls * Research and analysis highlights There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The top five pursued cancer indications are: breast cancer, leukemia, lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. , lymphoma and prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . A thorough target analysis of drugs in development reveals more than 130 candidate targets for triggering apoptosis in cancer cells. Competitive forces are reviewed, showing market leaders, active players and changes in the competitive landscape. There are only one big pharma company represented among the top 10 players in apoptopic drug development in oncology. The acquisition of Idun Pharmaceutical in 2005 by Pfizer is a principal example of a further step in big pharma strategy to augment their internal research and development efforts with high-potential, externally sourced product candidates and technologies. Key reasons to read this report * Understand the clinical and strategic challenges to the commercialization of apoptopic cancer drugs * Assess opportunities and risks for the continued development of apoptopic agents in five major cancer indications. * Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development Some of the almost 80 drugs included in this analysis: 2-methoxyestradiol, AEE-788, aglycon aglycon /agly·con/ (a-gli´kon) the noncarbohydrate group of a glycoside molecule. protopanaxadiol, aplidine, ARQ-501, arsenic trioxide arsenic trioxide Warning - Hazardous drug! Trisenox Pharmacologic class: Nonmetallic element, white arsenic Therapeutic class: Antineoplastic , BMS-387032, canertinib dihydrochloride, canfosfamide hydrochloride hydrochloride /hy·dro·chlo·ride/ (-klor´id) a salt of hydrochloric acid. hy·dro·chlo·ride n. A compound resulting from the reaction of hydrochloric acid with an organic base. , combretastatin A-4 prodrug, idronoxil, indisulam, INGN-201, mapatumumab, motexafin gadolinium, oblimersen sodium, OGX-011, patupilone, PXD-101, rubitecan, tipifarnib, trabectedin etc. Companies Mentioned include: * Alfacell Corporation * AnorMED * Antigenics * Antisoma * ArQule * Array BioPharma * Attenuon * Bionovo * Bristol-Myers Squibb * Cephalon Ceph´a`lon n. 1. (Zool.) The head. * ChemGenex Pharmaceuticals * Cougar cougar: see puma. cougar or puma or mountain lion or panther Species (Puma concolor) of large, graceful cat that lives in a wide variety of habitats in the Americas, from southern Alaska to Patagonia. Biotechnology * Cyclacel Group * Eisai, Eli Lilly * EntreMed * Erimos * Gardant gar·dant adj. Heraldry Variant of guardant. Adj. 1. gardant - looking forward full-face, guardant heraldry - the study and classification of armorial bearings and the tracing of genealogies * Gemin X Biotechnologies * Genta * Geron * GPC Biotech * Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. * Introgen Therapeutics * Johnson & Johnson * Lorus Therapeutics * Madaus * MethylGene * Novartis * Novogen * OncoGenex Technologies * OXiGENE * PanaGin * Pfizer * Pharmacyclics * PharmaMar * Seattle Genetics * SuperGen * Taxolog * Telik * TopoTarget * ViroTarg * ZymoGenetics For more information visit http://www.researchandmarkets.com/reports/c48447. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion